ID   SK-MEL-93 DX-B
AC   CVCL_A435
SY   DX-B; DX B
DR   Wikidata; Q54954347
RX   PubMed=2886213;
RX   PubMed=6976407;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5651 ! SK-MEL-93 DX-1
OI   CVCL_5652 ! SK-MEL-93 DX-2
OI   CVCL_5650 ! SK-MEL-93 DX-3
OI   CVCL_A432 ! SK-MEL-93 DX-4
OI   CVCL_A433 ! SK-MEL-93 DX-5
OI   CVCL_A434 ! SK-MEL-93 DX-6
SX   Female
AG   71Y
CA   Transformed cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 13
//
RX   PubMed=2886213;
RA   Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.;
RT   "Loss of heterozygosity at autosomal and X-linked loci during tumor
RT   progression in a patient with melanoma.";
RL   Cancer Res. 47:3995-4000(1987).
//
RX   PubMed=6976407; DOI=10.1084/jem.154.6.1764; PMCID=PMC2186539;
RA   Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Heterogeneity in surface antigen and glycoprotein expression of cell
RT   lines derived from different melanoma metastases of the same patient.
RT   Implications for the study of tumor antigens.";
RL   J. Exp. Med. 154:1764-1778(1981).
//